Compare JCSE & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JCSE | BGMS |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | Singapore | Malaysia |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.0M |
| IPO Year | 2022 | N/A |
| Metric | JCSE | BGMS |
|---|---|---|
| Price | $1.04 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 89.3K | 30.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.74 |
| 52 Week High | $2.50 | $6.70 |
| Indicator | JCSE | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 37.14 |
| Support Level | $0.89 | $0.74 |
| Resistance Level | $1.15 | $1.12 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 43.41 | 7.63 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.